Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for diagnosing cerebral infarction of white matter lesion patient and application of biomarker

A biomarker, cerebral infarction technology, applied in disease diagnosis, biological testing, biomaterial analysis, etc., can solve the problems of moving patients, high cost, unfavorable patient treatment and recovery, etc.

Active Publication Date: 2021-09-28
BAO FENG BIOTECH (BEIJING) CO LTD
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pathogenesis of cerebral infarction combined with white matter lesions is still unclear, and there is a lack of clear and effective therapeutic targets clinically, which is not conducive to the treatment and recovery of patients
At present, imaging methods such as CT and MRI are used for the diagnosis of cerebral infarction and white matter lesions, but they have disadvantages such as complicated operation, need to move patients, and high cost. It has important clinical value in guiding the treatment of stroke and improving the prognosis of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for diagnosing cerebral infarction of white matter lesion patient and application of biomarker
  • Biomarker for diagnosing cerebral infarction of white matter lesion patient and application of biomarker
  • Biomarker for diagnosing cerebral infarction of white matter lesion patient and application of biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] (1) Patient population standard

[0034] 1. The model building sample group is 102 people (internal population, which refers to the sample group used when building the prediction model)

[0035] Control group: 54 people with hyperintensity in brain white matter detected by MRI and no history of cerebral infarction, male to female ratio: 1:1, age range: over 45.

[0036] Patient population: 48 patients were sent to the hospital due to acute cerebral infarction due to MRI nuclear magnetic resonance examination showing high signal in the white matter of the brain. The male to female ratio: 1:1, and the age range: over 45.

[0037] 2. Model validation sample group 168 people (external population)

[0038] The sampling standard is the same as above.

[0039] Experimental equipment and reagents:

[0040] Sample collection: The serum of patients with only cerebral white matter lesions and cerebral infarction combined with white matter lesions were selected for testing.

[...

Embodiment 2

[0071] The logistic regression model was verified using an external data set, and the sampling standard was the same as in Example 1. This group provided 168 people, among whom hyperintensities appeared in the white matter of the brain, and 94 people who were sent to the hospital due to acute cerebral infarction showed hyperintensities in the white matter of the brain and anencephaly. 74 people with a history of infarction. Using the method in Example 1 to perform ultra-high performance liquid chromatography-mass spectrometry to detect the above 6 biomarkers, to verify the accuracy of the model results in Example 1, and draw the corresponding ROC curve, the results are as follows Show:

[0072] "Model A" variable is F1+F2, and the result of the ROC curve is as follows Figure 7 , Sensitivity (sensitivity)=1, Specificity (specificity)=1, Accuracy (accuracy)=1.

[0073] The "Model B" variable is F1+F3, and the results of the ROC curve are as follows Figure 8 As shown, Sensit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a biomarker phosphatidylinositol (22: 0 / 19: 0) in preparation of a detection reagent for diagnosing cerebral infarction of a white matter lesion patient. The risk of cerebral infarction of the white matter lesion patient is judged by combining the biomarker lipophosphatidylinositol (22: 0 / 19: 0) with glucosylceramide (d18: 0 / 24: 1 (15Z)), beta-hydroxyethyl ethanolamine, tomatidine, phosphatidylserine (22: 6 / 20: 1) or decanoyl carnitine. Cerebral infarction can be prevented in advance.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a biomarker for diagnosing cerebral infarction in patients with leukoencephalopathy and its application. Background technique [0002] With the aging of society, the incidence of stroke has increased sharply, and the incidence of stroke in our country is higher than the international average level. Among them, ischemic stroke (cerebral infarction) is caused by the stenosis or occlusion of cerebral arteries resulting in the loss of brain tissue. Blood necrosis accounts for more than 70% of all strokes. White matter lesion (WML) is a common neurodegenerative disease, the most typical pathological manifestations are damage to the integrity of white matter or demyelination, which is common in stroke, Parkinson's disease, Alzheimer's disease Alzheimer's disease, multiple sclerosis, schizophrenia and many other diseases. The typical response of white matter t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/32G01N30/34G01N30/72G01N30/86G01N33/50
CPCG01N30/02G01N30/06G01N30/32G01N30/34G01N30/72G01N30/8675G01N33/50G01N2203/0025G01N2203/0256G01N2800/2871G01N2800/50
Inventor 陈显扬宋王婷张珂韩佳睿薛腾
Owner BAO FENG BIOTECH (BEIJING) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com